This company listing is no longer active

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Athersys jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

OTCPK:ATHX.Q - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2023	0	-38	-25	-26	N/A
6/30/2023	0	-47	-31	-33	N/A
3/31/2023	2	-58	-45	-45	N/A
12/31/2022	5	-73	-59	-59	N/A
9/30/2022	6	-81	-69	-66	N/A
6/30/2022	11	-84	-78	-76	N/A
3/31/2022	8	-83	-81	-79	N/A
12/31/2021	6	-87	-78	-76	N/A
9/30/2021	6	-87	-76	-74	N/A
6/30/2021	1	-94	-76	-74	N/A
3/31/2021	1	-90	-68	-67	N/A
12/31/2020	1	-79	-63	-62	N/A
9/30/2020	0	-66	-56	-55	N/A
6/30/2020	0	-56	-44	-43	N/A
3/31/2020	4	-47	-43	-42	N/A
12/31/2019	6	-45	-36	-35	N/A
9/30/2019	7	-46	-30	-30	N/A
6/30/2019	10	-44	-30	-29	N/A
3/31/2019	25	-27	-14	-13	N/A
12/31/2018	24	-24	-15	-13	N/A
9/30/2018	24	-26	-16	-15	N/A
6/30/2018	22	-24	-15	-14	N/A
3/31/2018	3	-37	-25	-24	N/A
12/31/2017	4	-32	-24	-24	N/A
9/30/2017	4	-26	-24	-24	N/A
6/30/2017	3	-25	N/A	-23	N/A
3/31/2017	3	-26	N/A	-24	N/A
12/31/2016	17	-15	N/A	-11	N/A
9/30/2016	27	-5	N/A	-10	N/A
6/30/2016	27	-5	N/A	-8	N/A
3/31/2016	27	1	N/A	-8	N/A
12/31/2015	12	-16	N/A	-14	N/A
9/30/2015	2	-27	N/A	-15	N/A
6/30/2015	1	-25	N/A	-17	N/A
3/31/2015	2	-23	N/A	-17	N/A
12/31/2014	2	-22	N/A	-26	N/A
9/30/2014	2	-25	N/A	-24	N/A
6/30/2014	3	-26	N/A	-24	N/A
3/31/2014	3	-33	N/A	-24	N/A
12/31/2013	2	-31	N/A	-23	N/A
9/30/2013	4	-24	N/A	-22	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if ATHX.Q's forecast earnings growth is above the savings rate (2.5%).

Ertrag vs. Markt: Insufficient data to determine if ATHX.Q's earnings are forecast to grow faster than the US market

Hohe Wachstumserträge: Insufficient data to determine if ATHX.Q's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if ATHX.Q's revenue is forecast to grow faster than the US market.

Hohe Wachstumseinnahmen: Insufficient data to determine if ATHX.Q's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if ATHX.Q's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Athersys Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus forecasts updated

Price target decreased to US$3.33

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Recent updates

Motion For Case Conversion Approved for Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

Athersys Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

CEO, Secretary recently bought US$55k worth of stock

Athersys, Inc. to Report Q3, 2022 Results on Nov 15, 2022

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Athersys Receives Non-Compliance Letter from Nasdaq

Athersys: Is Big Pharma Sleeping At The Wheel?

Athersys extends exercise period of warrants in connection with recent offering

Athersys announces 1-for-25 reverse stock split

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Athersys, Inc. Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study

Athersys, Inc. Appoints Kasey Rosado as Interim Chief Financial Officer

Kasey Rosado named interim CFO of Athersys

Athersys, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Athersys: Dead Man Walking

Athersys, Inc. Designates Dan Camardo as the Principal Financial Officer and Principal Accounting Officer

Athersys, Inc. Announces Board Changes

Athersys, Inc. Announces Management Changes

Athersys, Inc., Annual General Meeting, Jun 15, 2022

Consensus forecasts updated

Athersys: Focus On Stroke

Athersys, Inc. to Report Q1, 2022 Results on May 06, 2022

Price target decreased to US$3.33

Athersys - Hero Or Zero Opportunity

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Athersys, Inc. to Report Q4, 2021 Results on Mar 15, 2022

Athersys, Inc. to Present an Outlook of its Ischemic Stroke Program Including Perspectives on the Upcoming TREASURE Study Data Readout

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Athersys, Inc. Announces Manuscript Reporting Data from the Company’s Must-ARDS Clinical Trial

Athersys: COVID-ARDS Is The Company's Most Important Target

Price target decreased to US$3.75

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Price target decreased to US$4.67

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Consensus forecasts updated

Consensus forecasts updated

Athersys: Subgroup Analysis As A Masterstroke

New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications

Athersys, Inc. announced that it expects to receive $100 million in funding from Aspire Capital Partners, LLC

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

Consensus revenue estimates fall to US$9.42m

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.29 loss in FY 2019)

Athersys, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021